Diabetic ketoacidosis induced by Alpelisib: A case report on a rare complication requiring emergency management
Open Access
- 16 January 2026
- journal article
- Published by Elsevier in JEM Reports
- Vol. 5 (1)
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Dynamics of hyperglycemia of patients treated with alpelisib: exploratory interim analysis of ITACA trialThe Oncologist, 2025
- Alpelisib-Induced Hyperglycemia in PIK3CA+ Breast Cancer PatientsSouthern Medical Journal, 2025
- Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi techniquenpj Breast Cancer, 2024
- Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated HyperglycemiaIntegrative Cancer Therapies, 2022
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1Annals of Oncology, 2021
- Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancerAnnals of Oncology, 2020
- Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2019
- Suppression of insulin feedback enhances the efficacy of PI3K inhibitorsNature, 2018
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast CancerClinical Cancer Research, 2017
- Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical TrialsMolecular Cancer Therapeutics, 2014